Metabolic and signaling interplay in the adipocyte-tumor microenvironment.
1/5 보강
Adipocytes are now recognized as active regulators of cancer progression and therapy resistance.
APA
Sivalingam AM (2026). Metabolic and signaling interplay in the adipocyte-tumor microenvironment.. The Journal of steroid biochemistry and molecular biology, 256, 106904. https://doi.org/10.1016/j.jsbmb.2025.106904
MLA
Sivalingam AM. "Metabolic and signaling interplay in the adipocyte-tumor microenvironment.." The Journal of steroid biochemistry and molecular biology, vol. 256, 2026, pp. 106904.
PMID
41253263 ↗
Abstract 한글 요약
Adipocytes are now recognized as active regulators of cancer progression and therapy resistance. Through metabolic, immune, and signaling interactions, they promote tumor cell proliferation, stemness, and survival. This review examines adipocyte tumor crosstalk in triple-negative breast cancer (TNBC) and oral squamous cell carcinoma (OSCC), focusing on how adipocyte-derived mediators influence tumor aggressiveness and treatment outcomes. Important adipocyte-secreted factors including complement C3, CXCL12, leptin, and adiponectin drive oncogenic signaling pathways that support tumor growth. In OSCC, C3/C3aR activation enhances cancer stemness, while in TNBC, bisphenol A-induced CXCL12 activates the CXCL12/CXCR4-PI3K/AKT axis, promoting epithelial-mesenchymal transition and therapy resistance. Additionally, circular RNAs and metabolic enzymes such as GCLC regulate HIF-1α, NF-κB, β-catenin, and mTOR pathways, further sustaining tumor progression. By establishing a tumor-supportive niche, adipocytes contribute significantly to therapy resistance. Targeting these adipocyte-tumor interactions represents a promising approach to inhibit oncogenic signaling and restore treatment sensitivity. Disrupting this metabolic crosstalk may reprogram the tumor microenvironment, offering new combinatorial strategies for aggressive cancers like TNBC and OSCC.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.